





PATENT 0147-0229P

IN THE U.S. PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant:

ECKERT, Helmut et al. Conf.:

2392

APR 0 1 2002

Appl. No.:

09/889,300

Group:

1645

TECH CENTER 1600/2900

Filed:

September 13, 2001 Examiner: unassigned

For:

USE OF ABTIBODIES FOR THE VACCINATION

AGAINST CANCER

## LETTER

January 25, 2002

Assistant Commissioner for Patents Office of Initial Patent Examination Customer Service Center Washington, DC 20231

Sir:

On the attached "Filing Receipt" in connection with the aboveidentified application, it is noted that there is a typographical error in the Title.

With the correction being underlined, the Filing Receipt should be corrected to have the Title read:

"Use of antibodies for anticancer vaccination"

"Use of antibodies for the vaccination against\_cancer"

Please enter the present Letter into the file of the aboveidentified application and provide a Corrected Notice incorporating the above correction.

If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

Loopard B. Syonasa

Leonard R. Svensson, #30,330

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

Attachments: Filing Receipt - (copy)

LRS/clh

0147-0229P

re religious for yoursons biroh, llp

, 2002



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
WWW.uspto.gov

 APPLICATION NUMBER
 FILING DATE
 GRP ART UNIT
 FIL FEE REC'D
 ATTY.DOCKET.NO
 DRAWINGS
 TOT CLAIMS
 IND CLAIMS

 09/889,300
 09/13/2001
 1645
 630
 0147-0229P
 13
 10
 1

**CONFIRMATION NO. 2392** 

2292 BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747

FILING RECEIPT

\*OC000000006797678\*

Date Mailed: 10/01/2001

RECEIVED
APR 0 1 2002

TECH CENTER 1600/2900

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Helmut Eckert, Oberwil, SWITZERLAND; Hans Loibner, Vienna, AUSTRIA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/EP00/00174 01/12/2000

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 51/99 01/13/1999

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

**Title** 

Use of antibodies for anticancer vaccination

177 - 3 2001

**Preliminary Class** 

435



## LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

## GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

## **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

